Cancer is a genetic disease, so prostate cancer is a genetic problem. This statement might be the most important one we can make when trying to describe the current, overall situation we face as prostate cancer survivors! Many institutions have begun significant research studies trying to understand the actual genetic keys to prostate cancer. Prostate [...]
There has been some surprising and unexpected news recently reported by John’s Hopkins Kimmel Cancer Center. Testosterone, which is believed to be a feeder of prostate cancer has been found to also suppress some advanced prostate cancers and also may reverse resistance the to the testosterone-blocking drugs (ADT) used to treat advanced prostate cancer. The [...]
Normally I don't write about pre-clinical things unless they are particularly interesting. You guessed it; I found a preclinical item that is interesting. According to a recent published study by Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University the receptor CCR5, which is targeted by already approved [...]
Sometimes scientific research is amazing! We are so lucky to have so many brilliant and gifted young people interested in conquering cancer. One of these brilliant young people is a doctoral student at Johns Hopkins, Andrew Wong. Mr Wong is a Ph.D. student studying materials science and engineering. Along with his facility advisor he has [...]
It has always been assumed that Ketoconazole, when used for the treatment of men with metastatic castration resistant prostate cancer (mCRPC), would not be as potent as abiraterone (Zytiga), but there has never been any head to head comparison to demonstrate this assumption! Ketoconazole is a less potent inhibitor of the CYP-17 enzyme, the mode [...]